KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) EBITDA (2016 - 2025)

Johnson & Johnson's EBITDA history spans 17 years, with the latest figure at $20.1 billion for Q4 2025.

  • For Q4 2025, EBITDA rose 5.65% year-over-year to $20.1 billion; the TTM value through Dec 2025 reached $39.9 billion, up 9.66%, while the annual FY2025 figure was $39.9 billion, 9.66% up from the prior year.
  • EBITDA for Q4 2025 was $20.1 billion at Johnson & Johnson, up from $7.0 billion in the prior quarter.
  • Across five years, EBITDA topped out at $20.1 billion in Q4 2025 and bottomed at $4.1 billion in Q1 2021.
  • The 5-year median for EBITDA is $6.6 billion (2021), against an average of $8.5 billion.
  • The largest annual shift saw EBITDA surged 85.91% in 2023 before it tumbled 45.17% in 2024.
  • A 5-year view of EBITDA shows it stood at $6.6 billion in 2021, then surged by 55.53% to $10.3 billion in 2022, then surged by 73.86% to $17.9 billion in 2023, then grew by 6.32% to $19.0 billion in 2024, then increased by 5.65% to $20.1 billion in 2025.
  • Per Business Quant, the three most recent readings for JNJ's EBITDA are $20.1 billion (Q4 2025), $7.0 billion (Q3 2025), and $6.6 billion (Q2 2025).